Windtree to Present at the Sidoti Micro Cap Conference on November 16th
08 11월 2023 - 10:00PM
Windtree Therapeutics, Inc. (“Windtree” or the “Company”)
(NasdaqCM: WINT), a biotechnology company focused on advancing
late-stage interventions for cardiovascular disorders, today
announced that Craig Fraser, President and Chief Executive Officer,
will present a corporate update at the Sidoti Micro Cap Conference
on Thursday, November 16, 2023 at 1:45pm ET. Windtree management
will also be participating in virtual 1x1 meetings with investors
at the event on November 15 and 16.
The corporate update presentation can be viewed live by clicking
on this link
https://sidoti.zoom.us/webinar/register/WN_roHsRn17R5m0wQo8wOIKsQ
or a recorded webcast may be accessed from the Events section of
Windtree’s website at https://ir.windtreetx.com/events.
About IstaroximeIstaroxime is a first-in-class
dual mechanism therapy designed to improve both systolic and
diastolic cardiac function. Istaroxime is a positive inotropic
agent that increases myocardial contractility through inhibition of
Na+/K+- ATPase with a complimentary mechanism that facilitates
myocardial relaxation through activation of the SERCA2a calcium
pump on the sarcoplasmic reticulum enhancing calcium reuptake from
the cytoplasm. Data from multiple Phase 2 studies in patients with
early cardiogenic shock or acute decompensated heart failure
demonstrate that istaroxime infused intravenously significantly
improves cardiac function and blood pressure without increasing
heart rate or the incidence of cardiac rhythm disturbances.
About Windtree Therapeutics, Inc.Windtree
Therapeutics, Inc. is advancing late-stage interventions for
cardiovascular disorders to treat patients in moments of crisis.
Using new scientific and clinical approaches, Windtree is
developing a multi-asset franchise anchored around compounds with
an ability to activate SERCA2a, with lead candidate, istaroxime,
being developed as a first-in-class treatment for cardiogenic shock
and acute decompensated heart failure. Windtree’s heart failure
platform includes follow-on pre-clinical SERCA2a activator assets
as well. In pulmonary care, Windtree has focused on facilitating
the transfer of the KL4 surfactant platform, to its licensee, Lee’s
Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.
Included in Windtree’s portfolio is rostafuroxin, a novel precision
drug product targeting hypertensive patients with certain genetic
profiles.
Contact Information:Matt
Epsteinmepstein@kendallir.com
Windtree Therapeutics (NASDAQ:WINT)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Windtree Therapeutics (NASDAQ:WINT)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024